Vita 34 : Close Brothers Seydler Starts Coverage of Vita 34 Stock

Vita 34 AG: Close Brothers Seydler Starts Coverage of Vita 34 Stock

Leipzig, 13 May 2014 - Vita 34 AG (WKN A0BL84), a pioneer in the storage of stem cells from umbilical cord blood and tissue, as well as a specialist in cryo-preservation, announces that the analysts at Close Brothers Seydler Research AG (CBS Research) have started coverage of the Vita 34 stock. In their initial research report, published today, the analysts have expressed a buy recommendation with a target price of EUR 7.10.

The analysts identified advances in the development of therapies using stem cells from umbilical cord blood and tissue, as well as a growing number of stem cell transplantation, as major drivers of growth. The variety of applications for autologous stem cells provides a great deal of potential to the field of regenerative medicine, and should contribute to increasing storage rates. In addition, the analysts see a positive effect on revenue growth from the strategic direction of expanding international activities via partners. Additional potential is offered by the expansion of the product range. For example, the introduction of the new product "VitaPlusNabelschnur" [VitaPlusCord] should have a significant effect on the group revenues and profits of Vita 34. In all, Vita 34 will use its corporate strengths, experience and innovative power to expand its already strong market position.

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, commented on the start of coverage: "We are pleased to again be able to provide our investors with an important source of information in the form of the current stock research report from CBS Research, in order to arrive at the most objective assessment of our growth potential possible. It is, moreover, a component of our significantly enhanced investor relations strategy aimed towards increasing the transparency of our company, and convincing additional private and institutional investors of the future opportunities available to Vita 34."

The complete research report is available for download as of today on the website at www.vita34group.de in the "Investor Relations" section.

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood.
The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissues are preserved alive at temperatures around minus 190 degrees Celsius, and can be used if needed in the context of medical treatment. Parents of more than 104,000 children are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34. To date, 26 therapeutic applications have been performed with stem cell preparations stored at Vita 34.